ОЗОН Фармацевтика Financial Statements (OZPH)
|
|
|
|
Report date
|
|
|
11.10.2024 |
11.10.2024 |
11.10.2024 |
24.04.2025 |
15.04.2026 |
|
15.04.2026 |
|
Currency
|
|
|
RUB |
RUB |
RUB |
RUB |
RUB |
|
RUB |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
Annual report URL
|
|
|
|
|
|
|
|
|
|
|
Presentation URL
|
|
|
|
|
|
|
|
|
|
|
|
Drug sales, bln pkg |
|
|
|
|
284.0 |
321.0 |
339.5 |
|
339.5 |
|
|
Revenue, bln rub |
? |
|
17.7 |
19.0 |
19.7 |
25.6 |
31.6 |
|
31.6 |
|
Operating Income, bln rub |
|
|
5.44 |
5.50 |
6.15 |
7.94 |
10.8 |
|
10.8 |
|
EBITDA, bln rub |
? |
|
6.04 |
6.82 |
7.47 |
9.48 |
12.2 |
|
12.2 |
|
Net profit, bln rub |
? |
|
3.95 |
3.65 |
4.00 |
4.61 |
6.17 |
|
6.17 |
|
|
OCF, bln rub |
? |
|
2.77 |
-0.994 |
4.66 |
5.83 |
3.25 |
|
3.25 |
|
CAPEX, bln rub |
? |
|
1.19 |
0.682 |
0.706 |
4.28 |
3.98 |
|
3.98 |
|
FCF, bln rub |
? |
|
1.26 |
-1.72 |
3.83 |
1.24 |
-0.302 |
|
-0.302 |
|
Dividend payout, bln rub
|
|
|
|
|
|
0.482 |
1.21 |
|
1.21 |
|
|
Dividend, rub/share
|
? |
|
|
|
|
0.44 |
1.07 |
|
1.07 |
|
Ordinary share dividend yield, %
|
|
|
0.0% |
0.0% |
0.0% |
1.1% |
2.1% |
|
2.3% |
|
Dividend payout ratio, %
|
|
|
0% |
0% |
0% |
10% |
20% |
|
20% |
|
|
OPEX, bln rub |
|
|
3.44 |
2.28 |
2.40 |
3.11 |
3.77 |
|
3.77 |
|
Cost of production, bln rub |
|
|
8.86 |
9.48 |
10.8 |
13.9 |
16.5 |
|
16.5 |
|
Amortization, bln rub |
|
|
0.6 |
0.7 |
0.9 |
1.1 |
1.2 |
|
1.2 |
|
R&D, bln rub |
|
|
|
|
|
0.325 |
0.641 |
|
0.641 |
|
Employment expenses, bln rub |
|
|
2.08 |
2.42 |
2.76 |
4.22 |
5.20 |
|
|
|
Interest expenses, bln rub |
|
|
0.570 |
1.000 |
1.15 |
2.48 |
3.90 |
|
3.90 |
|
|
Assets, bln rub |
|
|
29.7 |
34.1 |
34.4 |
49.5 |
53.2 |
|
53.2 |
|
Net Assets, bln rub |
? |
|
12.8 |
14.7 |
16.0 |
25.3 |
33.2 |
|
33.2 |
|
Debt, bln rub |
|
|
7.91 |
11.4 |
9.26 |
15.5 |
11.8 |
|
11.8 |
|
Cash, bln rub |
|
|
1.37 |
1.11 |
0.950 |
5.59 |
2.84 |
|
2.84 |
|
Net debt, bln rub |
|
|
6.53 |
10.3 |
8.31 |
9.94 |
8.98 |
|
8.98 |
|
|
Ordinary share price, rub |
|
|
35.0 |
35.0 |
35.0 |
41.5 |
51.5 |
|
47.0 |
|
Number of ordinary shares, mln |
|
|
1 000 |
1 000 |
1 000 |
1 099 |
1 168 |
|
1 168 |
|
Free Float, % |
|
|
|
|
|
7.70% |
20.0% |
|
20.0% |
|
Insider ownership, % |
|
|
|
|
|
40.1% |
37.7% |
|
37.7% |
|
|
Market cap, bln rub |
|
|
35.0 |
35.0 |
35.0 |
45.6 |
60.1 |
|
54.9 |
|
EV, bln rub |
? |
|
41.5 |
45.3 |
43.3 |
55.5 |
69.1 |
|
63.8 |
|
Book value, bln rub |
|
|
12.7 |
14.4 |
15.7 |
18.5 |
23.7 |
|
23.7 |
|
|
EPS, rub |
? |
|
3.95 |
3.65 |
4.00 |
4.20 |
5.28 |
|
5.28 |
|
FCF/share, rub |
|
|
1.26 |
-1.72 |
3.83 |
1.13 |
-0.26 |
|
-0.26 |
|
BV/share, rub |
|
|
12.7 |
14.4 |
15.7 |
16.9 |
20.3 |
|
20.3 |
|
|
EBITDA margin, % |
? |
|
34.2% |
36.0% |
37.9% |
37.1% |
38.6% |
|
38.6% |
|
Net margin, % |
? |
|
22.4% |
19.3% |
20.3% |
18.0% |
19.5% |
|
19.5% |
|
FCF yield, % |
? |
|
3.6% |
-4.9% |
10.9% |
2.7% |
-0.5% |
|
-0.6% |
|
ROE, % |
? |
|
30.8% |
24.9% |
25.1% |
18.2% |
18.6% |
|
18.6% |
|
ROA, % |
? |
|
13.3% |
10.7% |
11.6% |
9.3% |
11.6% |
|
11.6% |
|
|
P/E |
? |
|
8.87 |
9.58 |
8.74 |
9.88 |
9.74 |
|
8.89 |
|
P/FCF |
|
|
27.7 |
-20.4 |
9.14 |
36.7 |
-199.0 |
|
-181.7 |
|
P/S |
? |
|
1.98 |
1.85 |
1.77 |
1.78 |
1.90 |
|
1.74 |
|
P/BV |
? |
|
2.76 |
2.42 |
2.23 |
2.46 |
2.53 |
|
2.31 |
|
EV/EBITDA |
? |
|
6.88 |
6.64 |
5.80 |
5.85 |
5.67 |
|
5.24 |
|
Debt/EBITDA |
|
|
1.08 |
1.50 |
1.11 |
1.05 |
0.74 |
|
0.74 |
|
|
Employees, people |
|
|
1 958 |
2 112 |
1 982 |
3 005 |
3 153 |
|
3 153 |
|
Labour productivity, mln rub/person/year |
|
|
9.01 |
8.98 |
9.95 |
8.51 |
10.0 |
|
10.0 |
|
Expenses per employee, thousand rub |
|
|
1 060 |
1 145 |
1 391 |
1 404 |
1 648 |
|
0 |
|
R&D/CAPEX, % |
|
|
0.00% |
0.00% |
0.00% |
7.59% |
16.11% |
|
16.11% |
|
|
CAPEX/Revenue, % |
|
|
7% |
4% |
4% |
17% |
13% |
|
13% |
|
| ОЗОН Фармацевтика shareholders |
